Rating Change
Citigroup reiterated its Neutral rating on Merck & Co., Inc. (NYSE:MRK) on October 12, 2026.
reiterateNYSE:MRK
Citigroup Reiterates Neutral Rating on Merck & Co., Inc. (MRK)
Citigroup reiterated its Neutral rating on Merck & Co., Inc. (NYSE:MRK) on October 12, 2026.
At publication ·
What changed
Merck & Co., Inc. (NYSE:MRK) · reiterate
- Firm
- Citigroup
- Rating
- Neutral to Neutral
- Price at event
- $145.45
- Market capitalization
- $248.8B
At a glance
Key takeaways
- Citigroup maintained a Neutral rating on Merck on October 12, 2026, with the stock trading at $145.45 and a market cap of $248.8 billion.
Market Context
Merck & Co., Inc. operates in the Healthcare sector. The stock currently trades at $145.45 with a market capitalization of $248.8B. The stock has gained 36.6% over the past 52 weeks.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Merck & Co., Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Merck & Co., Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | Citigroup | Neutral | N/A |
| Oct 12, 2026 | RBC Capital | Sector Perform | N/A |
| Oct 08, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Oct 07, 2026 | Morgan Stanley | Overweight | N/A |
| Oct 05, 2026 | JP Morgan | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View MRK Stock Page
Frequently Asked Questions
What does the Neutral rating mean for MRK?
A rating of Neutral from Citigroup reflects the analyst's outlook on Merck & Co., Inc. (NYSE:MRK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRK forecast page.
